Trevi Therapeutics, Inc. Share Price & Technical Analysis
TRVI · $14.13 (-0.21%)
Healthcare / Biotechnology
$14.13
-0.21%
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
1% return in May, -17% avg return in past 3 year May month.
12% return in 2026, 97% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -17% | 13% | 1% | 13% | 1% | – | – | – | – | – | – | – | 12% |
| 25 | -5% | 15% | 40% | 13% | -6% | -20% | 32% | -1% | 26% | 29% | 13% | -5% | 132% |
| 24 | 0% | 93% | 21% | -15% | -10% | 15% | 7% | 0% | 6% | -15% | -3% | 46% | 146% |
| 23 | 21% | 0% | -17% | 79% | -35% | 9% | 4% | -8% | 0% | -18% | -39% | 18% | 14% |
| 22 | -25% | -14% | 214% | 17% | -11% | 17% | 11% | 3% | -53% | 25% | -5% | 0% | 179% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.08B
P/E ratio
—
52W high
$16.12
52W low
$5.38
Volume
13,23,227
Beta
1.08
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Trevi Therapeutics, Inc. share price today?
- Trevi Therapeutics, Inc. (TRVI) last traded around $14.13 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TRVI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TRVI. Download the app for real-time alerts.
- How can I analyze Trevi Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.